Eli Lilly acquires Synthego for $7.8 billion to enter sleep disorder drug market
Eli Lilly, a leading American pharmaceutical company, has announced its acquisition of Synthego for <strong>$7.8 billion</strong>, marking its entry into the growing sleep disorder medication market. This strategic move aims to expand the company's portfolio and enhance its position in the pharmaceutical industry.